819 Hits in 11.4 sec

Clinical utility of FDG-PET for the clinical diagnosis in MCI

Javier Arbizu, Cristina Festari, Daniele Altomare, Zuzana Walker, Femke Bouwman, Jasmine Rivolta, Stefania Orini, Henryk Barthel, Federica Agosta, Alexander Drzezga, Peter Nestor, Marina Boccardi (+2 others)
2018 European Journal of Nuclear Medicine and Molecular Imaging  
However, the high negative predictive value of FDG-PET and the existence of different disease-specific patterns of hypometabolism support the consensus recommendations for the clinical use of this imaging  ...  of FDG-PET, as added on clinical-neuropsychological examination, to ascertain the aetiology of MCI (AD, FTLD or DLB).  ...  Therefore, one of the main strengths of FDG-PET over other biomarkers (i.e. amyloid imaging or CSF) lies on its high predictive value for short-term conversion to AD in MCI subjects, in turn offering clinically  ... 
doi:10.1007/s00259-018-4039-7 pmid:29704037 fatcat:qy6zagei4zh3zeq2pp43tkvorm

Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series

Annapaola Prestia, Anna Caroli, Karl Herholz, Eric Reiman, Kewei Chen, William J. Jagust, Giovanni B. Frisoni
2013 Alzheimer's & Dementia  
atrophy, cortical hypometabolism, and cerebrospinal fluid (CSF) biomarkers were assessed in 18 MCI patients with prodromal AD (pAD, conversion time = 26±12 months) and 18 stable MCI patients (sMCI) from  ...  Results-Sensitivity to predict MCI conversion to AD in ADNI and TOMC cohorts was 79% and 94% based on Aβ42, 46% and 28% based on hippocampal volumes, 33 to 66% and 56 to 78% based on different hypometabolism  ...  Prodromal AD was defined as a diagnosis of MCI at baseline followed by conversion to AD during follow-up period; MCI patients who converted to non-AD dementia were excluded from the study.  ... 
doi:10.1016/j.jalz.2012.09.016 pmid:23375562 pmcid:PMC4058442 fatcat:c63hq4jy7fclvku4qrvw2gbrlm

Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI

Fayçal Ben Bouallègue, Denis Mariano-Goulart, Pierre Payoux, Babak Ardekani
2018 Journal of Alzheimer's Disease  
This study attests the complementary value of amyloid and FDG PET in MCI assessment and the efficiency of combined cognitive, amyloid, and metabolic scores to predict AD conversion.  ...  of 684 subjects from the ADNI (251 normal, 204 stable MCI, 85 AD converters, and 144 AD).  ...  ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association  ... 
doi:10.3233/jad-170833 pmid:29439345 fatcat:5nvmbblzdfhqthht22j26pxagu

Dissection of prodromal Alzheimer rsquo s disease

Ying Han
2018 Frontiers in Bioscience  
To identify individuals with high risk of conversion to AD and apply the research concept of prodromal AD into clinical practice, the utility of various biomarkers for distinguishing prodromal AD is evaluated  ...  Additionally, clinical management focusing on the stage of prodromal AD is summarized in this review for dementia prevention.  ...  Using FDG-PET, posterior precuneus and cingulate are thought to be the brain regions with potential value for predicting AD progression from MCI (45, 46) .  ... 
doi:10.2741/4643 pmid:28930599 fatcat:5yzeruxgl5evpi2buq4qxmezru

Individual brain metabolic connectome indicator based on Kullback-Leibler Divergence Similarity Estimation predicts progression from mild cognitive impairment to Alzheimer's dementia

Min Wang, Alzheimer's Disease Neuroimaging Initiative, Jiehui Jiang, Zhuangzhi Yan, Ian Alberts, Jingjie Ge, Huiwei Zhang, Chuantao Zuo, Jintai Yu, Axel Rominger, Kuangyu Shi
2020 European Journal of Nuclear Medicine and Molecular Imaging  
risk of conversion from MCI to AD.  ...  FDG-PET data consisting of 50 healthy controls, 332 patients with stable MCI, 178 MCI patients progressing to AD, and 50 AD patients were recruited from ADNI database.  ...  We obtained the metabolic difference patterns associated with conversion from MCI to AD.  ... 
doi:10.1007/s00259-020-04814-x pmid:32318784 pmcid:PMC7567735 fatcat:csa7ibhrd5g7zmsl2e4kpynfcy

Leading role of 18F-FDG-PET imaging in early diagnosis of Alzheimer's disease: an overview

Giorgio Treglia, Cason
2011 Research and Reports in Nuclear Medicine  
Furthermore FDG-PET imaging may help to discriminate the subjects of a high-risk population (like patients with mild cognitive impairment) who more probably will develop AD: an early stage of AD generally  ...  The combination of FDG-PET with other biomarkers, such as genotype, cerebrospinal fluid markers, and amyloid plaque imaging, may increase the preclinical diagnostic accuracy and offer promising approaches  ...  to AD from the stage of amnestic MCI.  ... 
doi:10.2147/rrnm.s16142 fatcat:y6owx6v3trcxtkxkpc72mpgjqq

FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort

Silvia Paola Caminiti, Tommaso Ballarini, Arianna Sala, Chiara Cerami, Luca Presotto, Roberto Santangelo, Federico Fallanca, Emilia Giovanna Vanoli, Luigi Gianolli, Sandro Iannaccone, Giuseppe Magnani, Daniela Perani (+6 others)
2018 NeuroImage: Clinical  
of conversion from MCI to AD dementia.  ...  Conclusions: Our results support the relevant role of FDG-PET-SPM classification in predicting progression to different dementia conditions in prodromal MCI phase, and in the exclusion of progression,  ...  Notably, a recent meta-analysis on a large sample of MCI (N = 97) has shown that adding FDG-PET imaging information to clinical data provides a better prediction of conversion from MCI to dementia in comparison  ... 
doi:10.1016/j.nicl.2018.01.019 pmid:29387532 pmcid:PMC5790816 fatcat:wvqbwe2ranhktkk3wlrvsmjyre

Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia

Michael Ewers, Reisa A. Sperling, William E. Klunk, Michael W. Weiner, Harald Hampel
2011 Trends in Neurosciences  
At the time of clinical manifestation of dementia, significant irreversible brain damage is already present, rendering the diagnosis of AD at early stages of the disease an urgent prerequisite for therapeutic  ...  In this Review, we discuss various neuroimaging measures that are proving to have potential value as biomarkers of AD pathology for the detection and prediction of AD before the onset of dementia.  ...  Additional support came from by NIH grants: P50 AG005133, R37 AG025516, P01 AG025204 (to BK), NIA: P01 AG036694; R01AG027435 (to RS), the Science Foundation Ireland (SFI) investigator neuroimaging program  ... 
doi:10.1016/j.tins.2011.05.005 pmid:21696834 pmcid:PMC3275347 fatcat:6dk62eqplrhlvckqy2c7cwcqdm

A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting

Leonardo Iaccarino, Konstantinos Chiotis, Pierpaolo Alongi, Ove Almkvist, Anders Wall, Chiara Cerami, Valentino Bettinardi, Luigi Gianolli, Agneta Nordberg, Daniela Perani
2017 Journal of Alzheimer's Disease  
Iaccarino et al. / FDG-and Amyloid-PET in MCI Conversion Prediction MCI to ADD conversion of both 18 F-FDG-PET and 11 C-PiB-PET imaging, the former showing optimal performance based on the SPM optimized  ...  Assessments of brain glucose metabolism ( 18 F-FDG-PET) and cerebral amyloid burden ( 11 C-PiB-PET) in mild cognitive impairment (MCI) have shown highly variable performances when adopted to predict progression  ...  None of the FDG-/Amy-subjects converted to AD, leading to 1.0 probability of nonconversion at about 10 years from MCI diagnosis.  ... 
doi:10.3233/jad-170158 pmid:28671117 fatcat:le5cfsib3ze33fcedirchbzvje

Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects

Michael Ewers, Matthias Brendel, Angela Rizk-Jackson, Axel Rominger, Peter Bartenstein, Norbert Schuff, Michael W. Weiner
2014 NeuroImage: Clinical  
In voxel-based analyses, FDG-PET and MRI GM maps were compared between HC converters and HC non-converters. Out of the 54 HC subjects, 11 subjects converted to MCI or AD dementia.  ...  those HC subjects who subsequently convert to mild cognitive impairment (MCI) or AD dementia.  ...  ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following:  ... 
doi:10.1016/j.nicl.2013.10.018 pmid:24286024 pmcid:PMC3841292 fatcat:vgxlvkasxnbxbbqoabh2rej2y4

A Survey of FDG- and Amyloid-PET Imaging in Dementia and GRADE Analysis

Perani Daniela, Schillaci Orazio, Padovani Alessandro, Nobili Flavio Mariano, Iaccarino Leonardo, Della Rosa Pasquale Anthony, Frisoni Giovanni, Caltagirone Carlo
2014 BioMed Research International  
This paper is a survey of the relevant literature on FDG and amyloid-PET imaging aimed at providing the value of quantification for the early and differential diagnosis of AD.  ...  Within the two major classes of AD biomarkers currently identified, that is, markers of pathology and neurodegeneration, amyloid- and FDG-PET imaging represent decisive tools for their measurement.  ...  Further, FDG-PET was found to perform better than SPECT and structural MR imaging in the prediction of conversion to AD in patients with MCI.  ... 
doi:10.1155/2014/785039 pmid:24772437 pmcid:PMC3977528 fatcat:nrufk45yfbhwhhift3ehe2dbbm

Potential neuroimaging biomarkers of pathologic brain changes in Mild Cognitive Impairment and Alzheimer's disease: a systematic review

Qingwei Ruan, Grazia D'Onofrio, Daniele Sancarlo, Zhijun Bao, Antonio Greco, Zhuowei Yu
2016 BMC Geriatrics  
With the development of new radioligands of neuroimaging, today it is possible to measure different aspects of AD neuropathology, early diagnosis of MCI and AD become probable from preclinical stage of  ...  The dynamic measures of these imaging biomarkers are used to predict the disease progression in the early stages and improve the assessment of therapeutic efficacy in these diseases in future clinical  ...  Conversely, the brain parenchymal fraction (BPF) which showed wholebrain atrophy, did not predict conversion from normal to MCI but predicted conversion to dementia [43] .  ... 
doi:10.1186/s12877-016-0281-7 pmid:27184250 pmcid:PMC4869390 fatcat:spci42k24rarvkagqslsivbfd4

Machine learning identified an Alzheimer's disease-related FDG-PET pattern which is also expressed in Lewy body dementia and Parkinson's disease dementia

Audrey Katako, Paul Shelton, Andrew L. Goertzen, Daniel Levin, Bohdan Bybel, Maram Aljuaid, Hyun Jin Yoon, Do Young Kang, Seok Min Kim, Chong Sik Lee, Ji Hyun Ko
2018 Scientific Reports  
Our data analyses confirmed that the support vector machine with Iterative Single Data Algorithm showed the best performance in prediction of future development of AD from the prodromal stage (mild cognitive  ...  Therefore, clinical reading of FDG-PET images is usually based on subjective impressions of the relative hypo-metabolism in key anatomical brain regions.  ...  A complete listing of ADNI investigators can be found at: apply/ADNI_Acknowledgement_List.pdf.  ... 
doi:10.1038/s41598-018-31653-6 pmid:30185806 pmcid:PMC6125295 fatcat:qftlf65x2zawbo2t3und24crka

Prediction of Mild Cognitive Impairment Conversion Using a Combination of Independent Component Analysis and the Cox Model

Ke Liu, Kewei Chen, Li Yao, Xiaojuan Guo
2017 Frontiers in Human Neuroscience  
Thus, it is necessary to explore and predict the onset of AD at the MCI stage.  ...  We first applied ICA to extract brain networks from structural MRI and FDG-PET images in AD and NC groups, respectively.  ...  No use, distribution or reproduction is permitted which does not comply with these terms.  ... 
doi:10.3389/fnhum.2017.00033 pmid:28220065 pmcid:PMC5292818 fatcat:h2jhl6p7ivgadh52gpeyo5a43y
« Previous Showing results 1 — 15 out of 819 results